

Index

- absence of benefit, defining, 305–6
- ABT-418, in attention-deficit hyperactivity disorder treatment, 278
- acetylcholine
 - breakdown, 294
 - half-life prolongation, 293
- acetylcholinesterase, inhibition, 294, 295
- activities of daily living (ADL), 306
 - assessment, 301
- acute bipolar depression, 22
 - pharmacotherapy, first-line, 28–35
 - studies, 34, 35
- acute delirium, 298
- acute mania, 22
 - pharmacotherapy, first-line, 23–8
 - polypharmacy, 28
 - studies, 24, 28
 - bias, 27
 - switch rates, 33
- ADAS *see* Alzheimer's Disease Assessment Scale (ADAS)
- Adderall
 - in attention-deficit hyperactivity disorder treatment, 257
 - dosage issues, 258
- Adderall XR
 - in attention-deficit hyperactivity disorder treatment, 267
 - dosage issues, 267
- ADHD *see* attention-deficit hyperactivity disorder (ADHD)
- adherence
 - in major depressive disorder treatment, 12
 - in social anxiety disorder treatment, 157
- ADL *see* activities of daily living (ADL)
- α -adrenergic agents, in attention-deficit hyperactivity disorder treatment, 275–8
- β -adrenergic blocking agents, in panic disorder treatment, 107
- α_2 -adrenergic receptor agonists, in panic disorder treatment, 107
- adults, attention-deficit hyperactivity disorder, 256–7
- agoraphobia
 - avoidance strategies, 107
 - definition, 105
 - differential diagnosis, 106
 - pharmacotherapy
 - combined, 116
 - meta-analyses, 112
 - prevalence, 106
- akathisia, 72
- alcohol, and panic disorder, 106
- alcohol abuse, and social anxiety disorder, 154
- alprazolam, 125
 - in panic disorder treatment, 108, 109–12
 - and posttraumatic stress disorder, 129
 - in social anxiety disorder treatment, 140, 145, 154
 - versus flesinoxan, 95–6
 - versus phenelzine, 140
 - versus pregabalin, 94–5
- Alzheimer's disease
 - with brain ischemia, 291
 - with cerebrovascular disease, 291
 - clinical trials, issues, 291–2
 - and dementia, 290
 - and depression, 292
 - diagnosis
 - accuracy, 291
 - clinical versus autopsy, 291–2

341 Index

- etiology, 312
- and folate deficiency, 313
- interventions, 292
 - types of, 292
- observational studies, 311–13
- pathology, 290
- pharmacotherapy
 - assessment, 293
 - drug holidays, 306
 - duration, 306–7
 - ethical issues, 298, 306, 307
 - evidence-based, 290–314
 - first-line, 293–306
 - outcomes measures, 301
 - prescribing issues, 292
- prevalence, 290
- and senile dementia compared, 290
- smoking and, 293–4
- treatment-resistant, pharmacotherapy, 313–14
- use of term, 290
- Alzheimer's Disease Assessment Scale (ADAS), 306
 - overview, 300
- amantadine, 278
- American Psychiatric Association (APA), eating
 - disorder guidelines, 243
- aminoketones, 272
- amisulpride
 - drug augmentation, 191
 - maintenance studies, 69
 - meta-analyses, 70
 - in schizophrenia treatment, 68–70
 - versus atypical antipsychotics, 69
 - versus conventional antipsychotics, 69
 - versus olanzapine, 63
 - versus placebo, 68–9
 - versus risperidone, 59
- amitriptyline
 - in anorexia nervosa treatment, 209–11
 - in attention-deficit hyperactivity disorder
 - treatment, 271
 - and bulimia nervosa, 219
 - with perhenazine, 322
 - in posttraumatic stress disorder treatment,
 - 125
 - versus clomipramine, 168
- amfetamines
 - dosage issues, 258
 - see also* dextroamfetamine
- AN *see* anorexia nervosa (AN)
- analysis of covariance (ANCOVA), 150
- anorexia nervosa (AN)
 - and body shape, 207
 - comorbidity, 206
 - diagnostic criteria, 204
 - pharmacotherapy, 207–19
 - efficacy studies, 205
 - long-term, 243
 - methodological issues, 239
 - response predictors, 242–3
 - short-term efficacy, 240–1
 - prevalence, 205
 - psychotherapy, 211
 - study resources, 205
 - symptoms, 204
 - treatment guidelines, 243
 - and weight gain, 207
 - and zinc deficiency, 216
 - see also* bulimia nervosa (BN)
- anticonvulsants
 - in acute bipolar depression treatment, 30–1
 - in acute mania treatment, 23–5
 - in bipolar disorder prophylaxis, 38–9, 43
 - in bulimia nervosa treatment, 228
 - in rapid-cycling bipolar disorder treatment, 43
- anti-dementia interventions, methodological
 - developments, 301
- antidepressants
 - in acute bipolar depression treatment, 32–3,
 - 35
 - and Alzheimer's disease, 292
 - in anorexia nervosa treatment, 240–1
 - anti-dementia activity, 292
 - in bipolar disorder prophylaxis, 41
 - development, 1, 2
 - future trends, 17
 - dosage issues, 114
 - drug augmentation, 14–15, 188
 - drug interactions, 322–3
 - dual-action, 2, 5–6
 - effectiveness, 5–6
 - early, 1
 - effectiveness, 2, 12, 17
 - age differences, 10
 - efficacy, 3, 113–14
 - in maintenance treatment, 11
 - mechanisms, 271
 - meta-analyses, 3, 4, 112
 - metabolism, 274
 - non-response, 12–13, 16
 - non-serotonergic, 168–9

342 Index

- antidepressants (*cont.*)
 - in panic disorder treatment, 107, 108–10, 112–14
 - in posttraumatic stress disorder treatment, 126–7, 130
 - in rapid-cycling bipolar disorder treatment, 42–3
 - response, 2
 - age differences, 10
 - sex differences, 9
 - selection criteria, 3
 - serotonergic versus non-serotonergic, 168–9
 - side-effects, 109
 - switching, 13
 - treatment duration issues, 10–12
 - trials, 2, 3
 - comparative, 8–9
 - triple-action, 2, 5–6
 - effectiveness, 5–6
 - versus benzodiazepines, 109–10, 111
 - see also* monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine (noradrenaline) reuptake inhibitors (SNRIs); serotonin reuptake inhibitors (SRIs); tricyclic antidepressants (TCAs)
- anti-inflammatory drugs, in Alzheimer's disease treatment, 312–13
- antipsychotics
 - in anorexia nervosa treatment, 207–9
 - in attention-deficit hyperactivity disorder treatment, 277
 - atypical
 - advantages, 78
 - comparisons, 75
 - versus conventional, 74–5
 - dosage issues, 75
 - drug augmentation, 190–1
 - drug interactions, 322
 - evaluation, 56
 - in panic disorder treatment, 107
 - in posttraumatic stress disorder treatment, 129
 - in schizophrenia treatment, 56
 - side-effects, 75
 - trials, 56, 76
- anxiety disorders
 - comorbidity, 8
 - versus panic disorder, 106
 - see also* generalized anxiety disorder (GAD); social anxiety disorder
- anxiolytics, 89
 - drug augmentation, 188
- APA (American Psychiatric Association), 243
- appetite, modulation, 214
- appetite enhancers, in anorexia nervosa treatment, 214–16, 217
- Aricept *see* donepezil
- aripiprazole, 27
 - maintenance treatment, 71
 - in schizophrenia treatment, 70–1
 - versus conventional antipsychotics, 70–1
 - versus placebo, 70–1
- arrhythmias, risk factors, 78
- ARTIST trial, 4
- atenolol, 148
 - in social anxiety disorder treatment, 139–41
 - versus phenelzine, 140
- atomoxetine
 - in attention-deficit hyperactivity disorder treatment, 274–5
 - efficacy, 275
 - side-effects, 275
 - versus placebo, 274–5
- attention-deficit hyperactivity disorder (ADHD)
 - adult, 256–7
 - behavior therapy, 278–9
 - costs, 255
 - diagnostic criteria, 255
 - drug holidays, 265
 - educational remediation, 258
 - etiology, 255–6
 - follow-up studies, 256
 - genetic bases, 256
 - morbidity, 255
 - and nicotinic dysregulation, 277–8
 - pathophysiology, 255–6
 - pharmacotherapy
 - cognitive effects, 258
 - drug classes, 259, 260, 261, 262, 263
 - duration, 278–9
 - evidence-based, 255–79
 - first-line, 257–75
 - prevalence, 255
 - prognosis, 256
 - and smoking risk, 277
 - and substance abuse, 264
 - subtypes, 255
 - symptoms, 255
- augmentation (drug) *see* drug augmentation
- axis II personality disorder, comorbidity, 8

343 Index

- BED *see* binge-eating disorder (BED)
- behavior therapy
 in attention-deficit hyperactivity disorder treatment, 278–9
 in panic disorder treatment, 107
see also cognitive-behavioral therapy (CBT)
- benzodiazepines, 27, 89
 and generalized anxiety disorder, 89, 96–7, 98
 in generalized anxiety disorder treatment, 94
 limitations, 99
 meta-analyses, 112
 in non-generalized social anxiety disorder treatment, 159
 and panic disorder, 106
 in panic disorder treatment, 107, 108, 109–10
 disadvantages, 113
 and posttraumatic stress disorder, 129
 prescribing issues, 94
 with selective serotonin reuptake inhibitors, 110, 114, 115
 side-effects, 94, 113
 in social anxiety disorder treatment, 145, 148, 151, 153–4
 with tricyclic antidepressants, 115
 versus antidepressants, 109–10, 111
 versus buspirone, 95
- benztropine, 66, 74
- Berkson's bias, 291
- beta-amyloid, accumulation reduction, 294
- beta-blockers
 in attention-deficit hyperactivity disorder treatment, 277
 drug interactions, 304
 in non-generalized social anxiety disorder treatment, 159
 in social anxiety disorder treatment, 146
- bethanechol, 214
- bias issues, negative studies, 27
- bilobalide, 310
- binge-eating disorder (BED)
 combined pharmacological/psychological treatment, 242
 diagnostic criteria, 204–5
 pharmacotherapy, 234–9
 efficacy studies, 205
 long-term, 242–3
 methodological issues, 240
 short-term efficacy, 241
 prevalence, 205
 study resources, 205
 symptoms, 204–5
 treatment guidelines, 244
- bioavailability (drug) *see* drug bioavailability
- bipolar disorder
 comorbidity, 22
 diagnosis, 12
 pharmacotherapy, evidence-based, 22–44
 polypharmacy, 43–4
 prevalence, 22
 prophylaxis
 pharmacotherapy, 28, 35–44
 studies, 36, 43–4
 rapid-cycling, 42–3
 recurrence, 11
 risk factors, 22
 study resources, 22–3
 type I, 33, 42
 type II, 33, 42
see also acute bipolar depression; acute mania; mania
- blood-brain barrier, 294, 303, 329
- blood clotting, 310
- blood pressure
 stimulant effects, 263–4
see also hypertension; hypotension
- BN *see* bulimia nervosa (BN)
- body shape, and anorexia nervosa, 207
- body weight
 and eating disorders, 206
 regulatory mechanisms, 206
see also weight gain
- bone mineral density, 77
- bradycardia, 304
- brain changes, and Alzheimer's disease, 290
- brain ischemia, 291
 with Alzheimer's disease, 291
 diagnosis, 291
- Brief Social Phobia Scale (BSPS), 146
- brofaromine, 2, 125
 in bulimia nervosa treatment, 222
 in posttraumatic stress disorder treatment, 125
 in social anxiety disorder treatment, 142, 152, 155
 versus placebo, 142
- bromazepam
 in social anxiety disorder treatment, 145, 154
 versus hydroxyzine, 96
- BSPS (Brief Social Phobia Scale), 146

344 Index

- bulimia nervosa (BN)
 - cognitive-behavioral therapy, short-term efficacy, 232–3
 - combined pharmacological/psychological treatment, 230–1, 241–2
 - meta-analyses, 231–4
 - short-term efficacy, 232–3
 - comorbidity, 206
 - diagnostic criteria, 204
 - future research, 244
 - improvement, 233
 - meta-analyses, 231–4
 - completion rates, 231–2
 - effect size, 232
 - exclusion criteria, 231–2
 - inclusion rates, 231–2
 - pharmacotherapy, 219–30
 - efficacy studies, 205
 - long-term, 242–3
 - long-term efficacy, 234
 - meta-analyses, 231–4
 - methodological issues, 239–40
 - response predictors, 242
 - short-term, 232
 - short-term efficacy, 232–3, 241
 - versus psychotherapy, 230–1
 - prevalence, 205
 - psychotherapy, 230–1
 - recovery rate, 233
 - study resources, 205
 - subtypes, 240
 - symptoms, 204, 239
 - post-treatment, 233–4
 - treatment guidelines, 243–4
 - see also* anorexia nervosa (AN)
- bupropion, 2
 - in acute bipolar depression treatment, 32–3
 - in attention-deficit hyperactivity disorder treatment, 269, 272–3
 - in bipolar disorder prophylaxis, 41
 - in bulimia nervosa treatment, 228, 229
 - effectiveness, 5, 15
 - pharmacology, 272–3
 - side-effects, 273
- bupirone, 148
 - in attention-deficit hyperactivity disorder treatment, 277
 - drug augmentation, 189
 - efficacy, 96, 99
 - in generalized anxiety disorder treatment, 95, 158
 - in posttraumatic stress disorder treatment, 129
 - in social anxiety disorder treatment, 146
 - versus venlafaxine, 93–4
- butyrylcholinesterase, inhibition, 294
- caffeine, and panic disorder, 106
- calcium channel blockers, 27
- calcium channels, voltage-gated, 94
- cannabis, 214–16
 - and panic disorder, 106
- CAPS (Clinician Adminstrated PTSD Scale), 121–2
- capsulotomy, 191–2
- carbamazepine, 23
 - in acute bipolar depression treatment, 29–30
 - in acute mania treatment, 25
 - in attention-deficit hyperactivity disorder treatment, 277
 - in bipolar disorder prophylaxis, 38, 43–4
 - in bulimia nervosa treatment, 228
 - in panic disorder treatment, 107
 - in posttraumatic stress disorder treatment, 128–9
- cardiac conduction block, 304
- cardiovascular dysfunctions, stimulant-induced, 263–4
- cardiovascular system, tricyclic antidepressant effects, 271–2
- Caregiver Activity Survey (CAS), 301
- catecholamine dysregulation, and attention-deficit hyperactivity disorder, 255, 256, 257
- catecholamines, 257
 - neurotransmission, 309
- CBT *see* cognitive-behavioral therapy (CBT)
- Celexa *see* citalopram
- cerebrovascular disease, 291
 - with Alzheimer's disease, 291
- CGI *see* Clinical Global Impression (CGI);
 Connors' Global Index
- ChEIs *see* cholinesterase inhibitors (ChEIs)
- Child Health Questionnaire, 275
- children, sudden death, 276–7
- chi-square test, 148, 150
- chlordiazepoxide, versus propranolol, 96
- 2'-chlorodesmethyldiazepam, versus paroxetine, 91
- m*-chlorophenylpiperazine, 89

345 Index

- chlorpromazine, 23, 25, 26, 74
 - in anorexia nervosa treatment, 207
 - and electroconvulsive therapy, 28
 - side-effects, 207
 - versus olanzapine, 73
 - versus quetiapine, 64–5
- cholecystokinin, 89
- cholinergic drugs
 - in Alzheimer's disease treatment, 293
 - cost-effectiveness, 304
- cholinergic system, defects, 295
- cholinesterase inhibitors (ChEIs), 292
 - in Alzheimer's disease treatment, 294–306
 - clinical issues, 303
 - in clinical practice, 305
 - cost-effectiveness, 304–5
 - in dementia with Lewy bodies treatment, 295
 - drug holidays, 306
 - issues, 306–7
 - drug interactions, 303–4
 - drug-switching issues, 305
 - efficiency, 305
 - mechanisms, 294–5
 - patient differences, 295–301
 - selection criteria, 303–4
 - side-effects, 301–2
 - in treatment-resistant Alzheimer's disease treatment, 313
 - types of, 294
 - in vascular dementia treatment, 295–8
- CIBIC-plus *see* Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)
- cingulotomy, 191–2
- cisapride, 214, 274
 - in anorexia nervosa treatment, 214
 - side-effects, 214
- citalopram, 1, 274
 - in anorexia nervosa treatment, 211
 - dose–response relationships, 179–80
 - drug-switching, 187–8
 - in generalized anxiety disorder treatment, 90
 - in obsessive-compulsive disorder treatment, 172, 175–6
 - in panic disorder treatment, 109
 - in posttraumatic stress disorder treatment, 126
 - versus escitalopram, 90
 - versus placebo, 172
- Clinical Global Impression (CGI), 139, 158, 183
 - benzodiazepine studies, 145
 - brofaromine studies, 142
 - fluoxetine studies, 171
 - fluvoxamine studies, 169, 226
 - moclobemide studies, 141
 - paroxetine studies, 143, 156
 - risperidone studies, 191
 - sertraline studies, 144, 175
 - treatment-response studies, 187
 - venlafaxine studies, 145
- Clinical Global Severity, 237
- Clinician Administered PTSD Scale (CAPS), 121–2
- Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)
 - applications, 300–1
 - overview, 300
- clomipramine
 - in anorexia nervosa treatment, 209
 - dosage issues, 178
 - dose–response relationships, 180
 - drug augmentation, 188–9
 - drug switching, 187–8
 - noradrenergic metabolites, 169
 - in obsessive-compulsive disorder treatment, 166–7, 174–5
 - with depression, 167–8
 - long-term, 182–3
 - without depression, 167
 - in panic disorder treatment, 109, 111–12
 - relapse rates, 184
 - side-effects, 176–8
 - versus clorgyline, 167, 168
 - versus desipramine, 168, 181
 - versus exposure therapy, 167
 - versus imipramine, 168
 - versus nortriptyline, 168
 - versus paroxetine, 171
 - versus selective serotonin reuptake inhibitors, 173–4, 176, 177, 181
 - versus venlafaxine, 182
 - withdrawal effects, 183–4
- Clomipramine Collaborative Group, 167
- clonazepam
 - in acute mania treatment, 27
 - and bipolar disorder prophylaxis, 41
 - drug augmentation, 189–90
 - in panic disorder treatment, 108, 109–10
 - in social anxiety disorder treatment, 145, 149, 152, 154, 158

346 Index

- clonidine
 - in attention-deficit hyperactivity disorder treatment, 275–8
 - dosage issues, 275–6
 - effects on noradrenergic system, 89
 - efficacy, 276
 - indications, 275
 - mechanisms, 275
 - with methylphenidate, 276–7
 - in panic disorder treatment, 107
 - in posttraumatic stress disorder treatment, 129
 - side-effects, 276
 - versus methylphenidate, 276
- clorgyline, versus clomipramine, 167, 168
- clozapine, 191
 - in acute mania treatment, 26
 - in bipolar disorder prophylaxis, 40–1
 - drug clearance, 326–7
 - in schizophrenia treatment, 72, 74
 - side-effects, 27, 59–60
 - versus risperidone, 59, 72–3
- cocaine, and panic disorder, 106
- Cochrane Collaboration
 - database, 90, 122
 - goals, 293
 - studies, 4–5, 7
 - imipramine, 96
 - limitations, 7
 - lithium, 35
 - rivastigmine, 303
- Cochrane Dementia and Cognitive Improvement Group, 295
- cognition, as outcomes measure, 301
- cognitive-behavioral therapy (CBT)
 - in bulimia nervosa treatment, 230–1, 241–2
 - meta-analyses, 232–3
 - short-term efficacy, 232–3
 - with diazepam, 98
 - in generalized anxiety disorder treatment, 98
 - in obsessive-compulsive disorder treatment, 178
 - in panic disorder treatment, 107, 110, 111, 114
 - in social anxiety disorder treatment, 140–1
 - in treatment-resistant social anxiety disorder, 158
 - versus phenelzine, 141, 153
 - versus risperidone, 71
- cognitive therapy (CT), in panic disorder treatment, 107, 111
- Cohen's *d*, 112, 148, 149, 150, 232
- comorbidity, major depressive disorder, 6–10
- Comprehensive Psychopathological Rating Scale (CPRS), 165
 - Obsessive-Compulsive subscale, 167
- Concerta
 - in attention-deficit hyperactivity disorder treatment, 265–6
 - efficacy, 265–6
 - mechanisms, 265
- Conners' ADHD/DSM-IV Scales, 267
- Conners' Global Index, 266
 - Scale for Teachers and Parents, 267
- corticotropin-releasing factor, 89
 - and posttraumatic stress disorder, 122
- cortisol, and posttraumatic stress disorder, 122
- CPRS *see* Comprehensive Psychopathological Rating Scale (CPRS)
- cryptoheptadine, in posttraumatic stress disorder treatment, 129
- CT *see* cognitive therapy (CT)
- Cylert *see* magnesium pemoline
- CYP enzymes *see* P450 enzymes
- cyproheptadine, in anorexia nervosa treatment, 209–11, 214
 - in posttraumatic stress disorder treatment, 129
- cytochrome P450 system, 274, 324
 - see also* P450 enzymes
- DAD (Disability Assessment for Dementia) scale, 301
- Davidson Trauma Scale (DTS), 121–2
- deep brain stimulation, 192
- dementia
 - age of onset, 290
 - concept of, 290
 - diagnosis, 308
 - etiology, 290, 291
 - and folate deficiency, 313
 - identification issues, 291–2
 - observational studies, 311–13
 - pharmacotherapy, outcomes measures, 301
 - prevalence, 290
 - see also* Alzheimer's disease; presenile dementia; senile dementia; vascular dementia
- dementia with Lewy bodies, 291
 - diagnosis, 291
 - pharmacotherapy, 295
- demographics, major depressive disorder, 6–10, 15–16
- depression
 - and Alzheimer's disease, 292
 - melancholic forms, 9

347 Index

- monoamine hypothesis, 1
- with obsessive-compulsive disorder,
 - pharmacotherapy, 167–8, 181
- and social anxiety disorder, 157
- subtypes, 6–10
- see also* acute bipolar depression; bipolar disorder; major depressive disorder (MDD)
- desipramine, 33, 125
 - in attention-deficit hyperactivity disorder treatment, 269–70, 271
 - in bulimia nervosa treatment, 219, 230
 - drug augmentation, 14–15
 - in posttraumatic stress disorder treatment, 125
 - versus clomipramine, 168, 181
 - versus cognitive-behavioral therapy, 230–1
 - versus fluvoxamine, 181
 - versus sertraline, 181
- dexamethasone suppression test, 206
- Dexedrine *see* dextroamphetamine
- dexmethylphenidate
 - activity, 267
 - in attention-deficit hyperactivity disorder treatment, 268
 - drug development, 267–8
- dextroamphetamine
 - in attention-deficit hyperactivity disorder treatment, 257
 - dosage issues, 258
- diabetes mellitus, 27, 76–7
- Diagnostic and Statistical Manual of Mental Disorders* (DSM)
 - binge-eating disorder, 204–5
 - dementia, 308
 - DSM-III, social anxiety disorder, 137, 149–50
 - DSM-III-R
 - generalized anxiety disorder, 88
 - social anxiety disorder, 137, 139, 149–50
 - DSM-IV
 - anorexia nervosa, 204
 - attention-deficit hyperactivity disorder, 255
 - bulimia nervosa, 204, 240
 - depressive subtypes, 6
 - generalized anxiety disorder, 88, 137
 - panic disorder, 105, 106
 - posttraumatic stress disorder, 121
 - social anxiety disorder, 137, 143, 149–50
- diazepam, 89
 - with cognitive-behavioral therapy, 98
 - in panic disorder treatment, 108
 - versus buspirone, 95
 - versus imipramine, 95
 - versus tetrahydrocannabinol, 214–16
 - versus venlafaxine, 93
- Disability Assessment for Dementia (DAD) scale, 301
- displacement interactions, 325, 330
- Dissertation Abstract, 147
- DMI *see* desipramine
- domperidone, 214
- donepezil
 - in Alzheimer's disease treatment, 294, 297, 298–300
 - benefits, 298
 - risk factors, 299
 - cost-effectiveness, 304–5
 - dosage issues, 295, 303
 - drug holidays, 307
 - drug interactions, 304
 - titration schemes, 302
 - trials, 301
 - in vascular dementia treatment, 295–8
 - versus galantamine, 302, 303
 - versus placebo, 301
 - versus rivastigmine, 302, 303
- L-dopa, 278
- dopamine, 1, 271
- dopamine agonists, 278
 - in acute bipolar depression treatment, 35
- dopamine receptor genes, and attention-deficit hyperactivity disorder, 256
- dopaminergic neurotransmission, 257
- droperidol, 78
- drug absorption
 - and food, 329
 - mechanisms, 327–9
- drug administration, oral, 327
- drug augmentation
 - antidepressants, 14–15
 - strategies, 15, 16
 - for treatment-resistant major depressive disorder, 13–15
 - for treatment-resistant obsessive-compulsive disorder, 188, 190–1
 - for treatment-resistant posttraumatic stress disorder, 128
 - for treatment-resistant social anxiety disorder, 158
- drug bioavailability
 - altered, 327–9
 - determinants, 329

348 Index

- drug clearance
 - definition, 325
 - and drug interactions, 324
 - elimination half-life, 324–5
 - hepatic, 325–6, 330–1
 - mechanisms, 325
 - organ clearance model, 325
 - renal, 325
 - roles, 324–7
- drug interactions, 320–37
 - antidepressants, 322–3
 - antipsychotics, 322
 - beta-blockers, 304
 - cholinesterase inhibitors, 303–4
 - classification, 323–4
 - issues, 321
 - costs, 320
 - daily exposure, 320
 - donepezil, 304
 - and drug clearance, 324
 - enzyme induction, 331–5
 - enzyme inhibition, 335–6
 - galantamine, 304
 - historical background, 321–3
 - in vivo* prediction, 336–7
 - monoamine oxidase inhibitors, 222, 322
 - mortality, 320
 - pharmaceutic, 323
 - pharmacodynamic, 323
 - pharmacokinetic, 321–2, 323–4
 - mechanisms, 327–36
 - protein-binding in, 327
 - psychoactive drugs, 320–1, 332
 - rivastigmine, 304
 - safety regulations, 322
 - selective serotonin reuptake inhibitors, 322–3
- drug metabolism, 328
 - in liver, 331
- drug–protein binding, reversibility, 330
- DSM *see* Diagnostic and Statistical Manual of Mental Disorders (DSM)
- DTS (Davidson Trauma Scale), 121–2
- duloxetine, 2

- Eating Attitudes Test, 226
- Eating Disorder Examination (EDE), 237
- Eating Disorder Inventory-2 (EDI-2), 226
 - olanzapine studies, 209
- eating disorders (EDs)
 - as affect disorders, 206
 - and body weight, 206
 - combined pharmacological/psychological treatment, 241–2
 - effects, 205
 - etiology, 204
 - future research, 244–5
 - long-term issues, 205
 - mortality rates, 205
 - pharmacotherapy, 206–7
 - classification, 205–6
 - efficacy studies, 205
 - evidence-based, 204–45
 - long-term, 242–3
 - methodological issues, 239–40
 - response predictors, 242
 - short-term efficacy, 240–1
 - prevalence, 204, 205
 - study resources, 205
 - treatment guidelines, 243–4
 - see also* anorexia nervosa (AN); binge-eating disorder (BED); bulimia nervosa (BN)
- ECA (Epidemiological Catchment Area), 22, 137
- ECT *see* electroconvulsive therapy (ECT)
- EDE (Eating Disorder Examination), 237
- EDI-2 *see* Eating Disorder Inventory-2 (EDI-2)
- EDs *see* eating disorders (EDs)
- effect size
 - in bulimia nervosa meta-analyses, 232
 - homogeneity versus heterogeneity, 150
 - measures, 148, 149, 150
 - adjusted, 151–2
 - observer-rated, 150
- Effexor *see* venlafaxine
- EGb 761
 - activity, 310
 - in Alzheimer's disease treatment, 310–11
 - applications, 310
 - side-effects, 310
- elderly
 - antidepressants, effectiveness studies, 10
 - orthostatic hypotension, 7
- electroconvulsive therapy (ECT), 191
 - in acute bipolar depression treatment, 32
 - in acute mania treatment, 28
 - in bipolar disorder prophylaxis, 42
- elimination *see* drug clearance
- elimination half-life, 324–5
- EMBase, 90
 - searches, 166
- enzyme induction
 - drug interactions, 331–5
 - mechanisms, 331–5

349 Index

- temporal issues, 335
- use of term, 331
- enzyme inhibition
 - clinical significance, 336
 - drug interactions, 335–6
 - mechanisms, 335–6
 - temporal issues, 336
- enzymes
 - hepatic, 326
 - phase I, 331
 - phase II, 331
 - see also* P450 enzymes
- Epidemiological Catchment Area (ECA) studies, 22, 137
- EPS *see* extrapyramidal symptoms (EPS)
- escitalopram, 1
 - efficacy, 96, 99
 - in generalized anxiety disorder treatment, 90–1
 - treatment duration, 97–8
 - in panic disorder treatment, 109
- estrogen, 312
 - trials, 312
- ethical issues, 298, 306, 307
- European Agency for the Evaluation of Medical Products, 308
- European Medicines Evaluation Agency, 301
- evidence-based pharmacotherapy of major depressive disorder, 1–17
- Exelon *see* rivastigmine
- Expert Consensus Panel for OCD, 178
 - Guidelines, 180, 186, 188
- exposure therapy
 - versus clomipramine, 167
 - versus sertraline, 144
- exposure *in vivo*, in panic disorder treatment, 107, 111
- extrapyramidal symptoms (EPS), 26
 - antipsychotic-induced, 74–5
 - and atypical antipsychotics, 78
 - olanzapine-induced, 62
 - reduction strategies, 74
 - risperidone-induced, 58, 59, 60
- Fear Questionnaire (FQ), 140
- fenfluramine, 278
 - d*-fenfluramine, in binge-eating disorder treatment, 237–9
- fixed effects model, versus random effects model, 150
- flavonoids, 310, 329
- flesinoxan
 - in generalized anxiety disorder treatment, 95–6
 - versus placebo, 95–6
- fluoxetine, 1, 125
 - in acute bipolar depression treatment, 32
 - in anorexia nervosa treatment, 211
 - in attention-deficit hyperactivity disorder treatment, 269, 273
 - axis II personality disorder studies, 8
 - in binge-eating disorder treatment, 237
 - in bipolar disorder prophylaxis, 41
 - in bulimia nervosa treatment, 222–6, 230
 - dose–response relationships, 179, 180, 186–7
 - drug augmentation, 14–15
 - drug interactions, 322–3
 - effectiveness, 4, 5
 - efficacy, 4
 - in generalized anxiety disorder treatment, 91
 - non-response, 13
 - in obsessive-compulsive disorder treatment, 170–1, 175–6
 - long-term, 183, 186–7
 - P450 enzyme inhibition, 337
 - in panic disorder treatment, 109
 - in posttraumatic stress disorder treatment, 125–6, 127–8
 - relapse rates, 184
 - response, sex differences, 9
 - versus clomipramine, 174–5
 - versus phenelzine, 168, 171
 - versus placebo, 170–1
- flupenthixol, 58
 - versus amisulpride, 69
- fluvoxamine, 1
 - in binge-eating disorder treatment, 234–7
 - in bulimia nervosa treatment, 222, 226–7
 - dosage issues, 178
 - in generalized anxiety disorder treatment, 91
 - in obsessive-compulsive disorder treatment, 169–70, 175–6, 182
 - in panic disorder treatment, 109, 111–12
 - in posttraumatic stress disorder treatment, 126
 - in social anxiety disorder treatment, 143–4, 148
 - versus clomipramine, 174–5
 - versus desipramine, 181
 - versus maprotiline, 109
 - versus placebo, 143–4, 169–70, 226–7
- Focalin *see* dexamethylphenidate
- folate deficiency, and dementia, 313
- food, and drug absorption, 329
- FQ (Fear Questionnaire), 140

350 Index

- Freud, Sigmund, 314
 frontostriatal dysfunction, and attention-deficit hyperactivity disorder, 255, 256, 257
- GABA (gamma-aminobutyric acid), 89, 94, 311
 gabapentin, 25
 in acute bipolar depression treatment, 30–1
 in bipolar disorder prophylaxis, 38
 in social anxiety disorder treatment, 146, 152, 155, 158
- GAD *see* generalized anxiety disorder (GAD)
- galactorrhea, 77
- galantamine
 in Alzheimer's disease treatment, 294, 297, 298
 benefits, 298
 risk factors, 299
 cost-effectiveness, 304–5
 dosage issues, 295
 drug interactions, 304
 titration schemes, 302, 305
 trials, 301
 in vascular dementia treatment, 295–8
 versus donepezil, 302, 303
 versus placebo, 301
- gamma-aminobutyric acid (GABA), 89, 94, 311
- gamma-aminobutyric acid/benzodiazepine receptor system, and generalized anxiety disorder, 89
- gastric motility, abnormal, 211–14
- generalized anxiety disorder (GAD)
 cognitive-behavioral therapy, 98
 comorbidity, 88–9, 99
 diagnostic criteria, 137
 neurotransmitter disturbances, 89–90
 pathophysiology, 89
 pharmacotherapy
 evidence-based, 88–99
 first-line, 90–7
 with psychotherapy, 98
 treatment duration, 97–8
 prevalence, 88, 98–9
 saccadic eye movement velocity, 89
 study resources, 90
 symptoms, 88
 treatment-resistant
 drug augmentation, 158
 pharmacotherapy, 98
 see also non-generalized anxiety disorder
 genetics, and attention-deficit hyperactivity disorder, 256
- ginkgo biloba (maidenhair tree), 313
 active compounds, 310
 in Alzheimer's disease treatment, 310–11
- ginkgolides, 310
- Glass's delta, 148
- gliosis, 309
- glucocorticoid receptors, and posttraumatic stress disorder, 122
- L-glutamate, functions, 307–8
- glutamatergic system, modulation, 307–8
- P-glycoprotein (P-gp)
 activity, 329
 and drug bioavailability, 329
 in drug metabolism, 328
 localization, 329
 substrates, 336
- grapefruit juice, and drug bioavailability, 329
- growth deficits, stimulant-induced, 264–5
- guanfacine, 276
 in attention-deficit hyperactivity disorder treatment, 275–6, 278
- Hachinski score, 308
- haloperidol
 in acute mania treatment, 26
 as antipsychotic comparator, 56, 74
 drug augmentation, 190
 in schizophrenia treatment, 74
 versus amisulpride, 69
 versus aripiprazole, 70, 71
 versus clozapine, 73–4
 versus olanzapine, 62–3, 72, 73–4
 versus quetiapine, 64, 73
 versus risperidone, 58, 60, 72, 73–4
 versus sertindole, 67–8
 versus ziprasidone, 66
- Hamilton Anxiety Rating Scale (HAM-A), 91
 citalopram studies, 90
 paroxetine studies, 91–2
 sertraline studies, 92–3
- Hamilton Depression Rating Scale (HAM-D), 4, 8, 9, 13, 14
 citalopram studies, 90
 clomipramine studies, 167
 olanzapine studies, 209
 valproate studies, 30
- Hedges' *g*, 151
- hepatic enzymes, roles, 326
- hepatocytes, drug metabolism, 326
- herbal drugs, 320

351 Index

- hippocampal region, reduced volume, 122
- hormone replacement therapy (HRT)
 in Alzheimer's disease treatment, 312
 benefits, 312
- HPA axis *see* hypothalamus–pituitary–adrenal (HPA) axis
- HRT *see* hormone replacement therapy (HRT)
- 5-HT *see* serotonin
- 5-hydroxyindoleacetic acid, 89
- 5-hydroxytryptamine (5-HT) *see* serotonin
- 5-hydroxytryptamine receptor agonists, in
 generalized anxiety disorder treatment,
 95–6
- hydroxyzine
 efficacy, 96
 in generalized anxiety disorder treatment,
 96
 versus placebo, 96
- hyperhomocysteinemia, 313
- hyperlipidemia, 313
- hyperprolactinemia
 antipsychotic-induced, 77
 risperidone-induced, 59
- hypertension
 and clonidine, 275
 withdrawal, 276
- hypertriglyceridemia, 76–7
- hyphema, 310
- hypoglycemia, 106
- hypogonadism, 77
- hypomania, prevalence, 22
- hypotension
 drug-induced, 292
 orthostatic, 7
- hypothalamus, 89
 medioventral, 206
- hypothalamus–pituitary–adrenal (HPA) axis, 122
 negative feedback inhibition, 122
- ICD (International Classification of Diseases),
 88–9
- idazoxan, 33
- imipramine, 1
 in acute bipolar depression treatment, 29
 in attention-deficit hyperactivity disorder
 treatment, 269, 271
 axis II personality disorder studies, 8
 in binge-eating disorder treatment, 234, 238
 in bipolar disorder prophylaxis, 41
 in bulimia nervosa treatment, 219, 230
 drug-switching studies, 13
 effectiveness, 5
 efficacy, 96
 in generalized anxiety disorder treatment, 95
 in panic disorder treatment, 109–10, 111–12
 treatment duration, 114–15
 in posttraumatic stress disorder treatment, 125
 response, sex differences, 9
 trials, 8–9
 versus clomipramine, 168
 versus paroxetine, 91
 versus placebo, 95, 96
- indometacin, in Alzheimer's disease treatment,
 312–13
- inositol, 125
 and posttraumatic stress disorder, 129
 in treatment-resistant obsessive-compulsive
 disorder, 191
- intent-to-treat (ITT) analysis
 in panic disorder studies, 110
 in social anxiety disorder studies, 142, 144, 146,
 152, 156
- International Classification of Diseases (ICD),
 ICD-10, generalized anxiety disorder, 88–9
- interpersonal psychotherapy (IPT), in bulimia
 nervosa treatment, 231
- ischemic stroke, 307
- isoniazid, 1
- ketoacidosis, diabetic, 26
- kidneys, drug clearance, 325
- lamotrigine, 25, 125
 in acute bipolar depression treatment, 30
 in bipolar disorder prophylaxis, 38, 42
 in posttraumatic stress disorder treatment,
 128
- leukoaraiosis, 291
- levetiracetam, 31
- Lexapro *see* escitalopram
- Liebowitz Social Anxiety Scale (LSAS), 146, 149
 benzodiazepine studies, 145
 brofaromine studies, 142
 fluvoxamine studies, 143
 in meta-analyses, 151
 moclobemide studies, 141
 paroxetine studies, 143
 sertraline studies, 144
 social avoidance subscale, 140, 141
 venlafaxine studies, 145

352 Index

- lithium
 - in acute bipolar depression treatment, 28, 35
 - in acute mania treatment, 23, 28
 - in anorexia nervosa treatment, 211
 - in bipolar disorder prophylaxis, 35–8, 43
 - in bulimia nervosa treatment, 227–8
 - drug augmentation, 13, 14–15, 16, 189
 - drug interactions, 322
 - mortality prophylaxis, 37–8
 - in panic disorder treatment, 107
 - in posttraumatic stress disorder treatment, 128–9
 - side-effects, 211
 - suicide prophylaxis, 37–8
 - trials, 23
 - versus placebo, 28
 - lithium carbonate, 13
 - liver
 - drug clearance, 325–6, 330–1
 - drug metabolism, 331
 - function, and magnesium pemoline, 264
 - LSAS *see* Liebowitz Social Anxiety Scale (LSAS)
 - Luvox *see* fluvoxamine
 - lymphocytes, binding, 89

 - MADRS (Montgomery Asberg Depression Rating Scale), 31
 - magnesium pemoline
 - in attention-deficit hyperactivity disorder treatment, 257
 - dosage issues, 258
 - side-effects, 264
 - magnetic resonance imaging (MRI),
 - attention-deficit hyperactivity disorder studies, 255–6
 - maintenance of effect assessment
 - continuation treatment design, 97
 - relapse-prevention design, 97
 - maintenance treatment
 - antidepressants in, 11
 - individual differences, 11
 - obsessive-compulsive disorder, 186
 - placebo studies, 11–12, 16
 - posttraumatic stress disorder, 127–8
 - studies, 16–17
 - major depressive disorder (MDD)
 - age differences, 10
 - atypical, comparative drug trials, 8–9
 - comorbidity, 6–10
 - anxiety disorders, 8
 - axis II personality disorder, 8
 - medical, 7–8
 - demographics, 6–10, 15–16
 - lifetime risk, 1
 - maintenance treatment, 11, 16
 - pharmacotherapy
 - adherence issues, 12
 - drug selection criteria, 3
 - duration, 10–12
 - evidence-based, 1–17
 - first-line, 3–10, 15
 - non-response, 16
 - trials, 2, 3
 - prevalence, 1
 - recurrence, 10
 - relapse
 - prediction, 10–11
 - risk, 12
 - sex differences, 9
 - subtypes, 8–9
 - treatment-resistant, drug augmentation, 13–15
 - pharmacotherapy, 12–15
-
- mania
 - prevalence, 22
 - study bias, 27
 - see also* acute mania
- MAOIs *see* monoamine oxidase inhibitors (MAOIs)
- maprotiline, versus fluvoxamine, 109
- marijuana, 264
- Maudsley Obsessive-Compulsive Inventory, 170
- MDD *see* major depressive disorder (MDD)
- MEDLINE, 2, 90
 - searches, 22, 105, 122, 139, 166
- melancholia, 206
- memantine
 - in Alzheimer's disease treatment, 307–8
 - early studies, 308
 - mechanisms, 307–8
 - versus placebo, 308
 - in treatment-resistant Alzheimer's disease treatment, 313
- meta-analyses
 - advantages, 2, 146
 - limitations, 173
 - overview, 146–7
- Metadate-CD, in attention-deficit hyperactivity disorder treatment, 266
- 3-methoxy-4-hydroxyphenylglycol, 89

353 Index

- N*-methyl-D-aspartate (NMDA), 307–8
 receptor antagonists, 308
- methylphenidate
 in attention-deficit hyperactivity disorder
 treatment, 257, 264, 266
 with clonidine, 276–7
 controlled delivery, 265, 266
 dosage issues, 258
 isomers, 267
 stereoselectivity, 267
 versus clonidine, 276
see also dexamethylphenidate
- methylphenidate immediate release (MPH IR)
 in attention-deficit hyperactivity disorder
 treatment, 265–6
 dosing, 265
- metoclopramide, 214
- mianserin
 in bulimia nervosa treatment, 228, 229
 drug augmentation, 14
 in obsessive-compulsive disorder treatment, 181
- mineral supplements, in bipolar disorder
 prophylaxis, 42
- Mini-Mental State Examination (MMSE), 298, 306
 overview, 300
- mirtazapine, 2, 274
 drug augmentation, 14
 effectiveness, 5, 15
 in obsessive-compulsive disorder treatment, 181
 in posttraumatic stress disorder treatment, 126
- MMSE *see* Mini-Mental State Examination (MMSE)
- moclobemide, 2, 149
 in acute bipolar depression treatment, 32
 in posttraumatic stress disorder treatment, 125
 in social anxiety disorder treatment, 140, 141–2, 152, 155
 versus placebo, 141–2
- monoamine hypothesis of depression, 1
- monoamine oxidase A, inhibition, 309
- monoamine oxidase B
 inhibition, 309
 localization, 309
- monoamine oxidase inhibitors (MAOIs), 1, 308
 in acute bipolar depression treatment, 32
 in attention-deficit hyperactivity disorder
 treatment, 269, 273
 in bulimia nervosa treatment, 222, 223, 233
 drug interactions, 222, 322
 limitations, 15
 in panic disorder treatment, 108, 109
 in posttraumatic stress disorder treatment, 125, 127
 response, sex differences, 9
 side-effects, 222, 273
 in social anxiety disorder treatment, 139–41, 148, 154–5
 trials, 8–9
see also reversible inhibitors of monoamine oxidase (RIMAs)
- monoamines, depletion, 1
- Montgomery Asberg Depression Rating Scale (MADRS), 31
- mood disorders, 22
- mood disturbances, stimulant-induced, 263
- mood stabilizers
 in anorexia nervosa treatment, 211, 213
 in bipolar disorder prophylaxis, 39, 41, 42
 in bulimia nervosa treatment, 227–8
 in panic disorder treatment, 107
 in posttraumatic stress disorder treatment, 128–9
- mortality
 drug interactions, 320
 lithium prophylaxis, 37–8
- MPH IR *see* methylphenidate immediate release (MPH IR)
- Multimodal Treatment Study for ADHD (MTA), 278–9
- muscarinic receptor agonists, 293
- nadolol, in attention-deficit hyperactivity disorder
 treatment, 277
- nalmefene, in posttraumatic stress disorder
 treatment, 129
- naltrexone
 in anorexia nervosa treatment, 214
 in binge-eating disorder treatment, 234, 237
 in bulimia nervosa treatment, 228
 in posttraumatic stress disorder treatment, 129
- National Comorbidity Survey (US), 1, 137
- National Institute of Clinical Excellence (UK), 304–5, 306
 guidelines, 306
- National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (US), 308
 criteria, 300, 311

354 Index

- National Institutes of Mental Health (NIMH) (US), 6, 17
- National Institutes of Mental Health Global Obsessive-Compulsive Scale (NIMH-OC), 167, 174, 184
 sertraline studies, 170
- NDRIs (norepinephrine (noradrenaline) dopamine reuptake inhibitors), 228
- nefazodone, 2
 in posttraumatic stress disorder treatment, 126
- neuroendocrine system disturbances, in
 posttraumatic stress disorder, 122
- neuroleptic agents
 in acute bipolar depression treatment, 31
 in acute mania treatment, 25–7
 and Alzheimer's disease, 292
 in bipolar disorder prophylaxis, 39, 40–1, 44
- Neuropsychiatric Inventory (NPI), 295, 301
- neurotransmitter disturbances
 in generalized anxiety disorder, 89–90
 in posttraumatic stress disorder, 122
- neurotransmitters, antidepressant effects on, 2, 271
- nicotine
 in Alzheimer's disease treatment, 293–4
 in attention-deficit hyperactivity disorder treatment, 278
- nicotinic dysregulation, and attention-deficit hyperactivity disorder, 277–8
- nicotinic receptor agonists, 293, 294
- NIMH (National Institutes of Mental Health) (US), 6, 17
- NIMH-OC *see* National Institutes of Mental Health Global Obsessive-Compulsive Scale (NIMH-OC)
- NINCDS-ADRDA *see* National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (US)
- NMDA *see* *N*-methyl-D-aspartate (NMDA)
- non-generalized anxiety disorder
 characteristics, 137
 treatment, 159
- non-serotonergic antidepressants, versus serotonin reuptake inhibitors, 168–9
- non-stimulants, in attention-deficit hyperactivity disorder treatment, 268–74
- noradrenaline, 89
- noradrenaline reuptake inhibitors
 in panic disorder treatment, 109
see also serotonin–norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
- noradrenergic neurotransmission, 257
- noradrenergic specific reuptake inhibitors (NSRIs), in attention-deficit hyperactivity disorder treatment, 274–5
- noradrenergic system, 206
 disturbances, 89
- norepinephrine, 1, 271
- norepinephrine (noradrenaline) dopamine reuptake inhibitors (NDRIs), in bulimia nervosa treatment, 228
- nortriptyline
 in attention-deficit hyperactivity disorder treatment, 269, 270, 271
 axis II personality disorder studies, 8
 effectiveness, 7
 versus clomipramine, 167, 168
- NSRIs (noradrenergic specific reuptake inhibitors), 274–5
- obsessive-compulsive disorder (OCD)
 age of onset, 165
 childhood, 168
 comorbidity, 165
 costs, 165
 with depression, 167–8, 181
 diagnosis, issues, 165–6
 diagnostic criteria, 165
 etiology, 166
 expert consensus guidelines, 178
 maintenance treatment, 186
 pharmacotherapy
 dosage issues, 178–80, 186–7
 dose-titration strategies, 180
 duration, 182–7
 evidence-based, 165–93
 first-line, 166–82
 long-term, 182, 186–7
 meta-analyses, 173
 response rates, 172
 trials, 166
 withdrawal effects, 183–4
- prevalence, 165
- rating scales, 165
- relapse, 183–4
 prevention, 184–6
- sex differences, 165
- studies

355 Index

- population-change effects, 172
 - resources, 166
- treatment-resistant
 - drug augmentation, 188
 - pharmacotherapy, 187–92
 - strategies, 187–8, 191–2
- treatment-response predictors, 187
- odds ratio (OR), 149
- OFC (olanzapine–fluoxetine combination), 31, 32
- olanzapine, 23, 125
 - in acute bipolar depression treatment, 31
 - in acute mania treatment, 26–7, 28
 - in anorexia nervosa treatment, 207, 209
 - in bipolar disorder prophylaxis, 39–40
 - drug augmentation, 15, 191
 - intramuscular, 62–3
 - maintenance treatment, 63
 - meta-analyses, 63
 - monotherapy, 31, 32
 - in posttraumatic stress disorder treatment, 129
 - in resistant schizophrenia treatment, 73
 - in schizophrenia treatment, 61–3, 71–2
 - side-effects, 26–7, 59–60
 - in social anxiety disorder treatment, 146
 - versus atypical antipsychotics, 63
 - versus conventional antipsychotics, 62
 - versus placebo, 61–2
 - versus risperidone, 59, 63
- olanzapine–fluoxetine combination (OFC), in
 - acute bipolar depression treatment, 31, 32
- omega-3 fatty acids, in bipolar disorder
 - prophylaxis, 42
- ondansetron, in bulimia nervosa treatment, 229, 230
- opiate antagonists
 - in anorexia nervosa treatment, 214, 216
 - in bulimia nervosa treatment, 228
- opioid peptide system, 214
- OR (odds ratio), 149
- oxcarbazepine
 - in acute bipolar depression treatment, 31
 - in acute mania treatment, 25
- 2-oxo-1-pyrrolidine acetamide *see* piracetam

- P450 enzymes, 323, 336
 - CYP1A2, induction, 331–5
 - CYP2D6, 331–5
 - inhibition, 337
 - CYP2E1, induction, 331–5
 - CYP3A4, induction, 331–5
 - in drug metabolism, 328, 331
 - induction, 331–5
 - inhibition, 337
- panic disorder (PD)
 - age of onset, 106
 - avoidance strategies, 107
 - comorbidity, 105, 106–7
 - definition, 105
 - diagnosis, 105–7
 - differential diagnosis, 106
 - etiology, 106
 - pharmacotherapy, 105–17
 - approaches, 105, 108–12
 - dosage issues, 108
 - first-line, 112–14, 117
 - long-term effects, 114–15
 - meta-analyses, 111–12
 - posttest studies, 113
 - with psychotherapy, 107
 - treatment duration, 114–15, 116
 - prevalence, 105, 106
 - psychotherapy, treatment duration, 116
 - relapse prevention, 115
 - study resources, 105
 - symptoms, 105
 - treatment
 - combination, 110–11, 116
 - cost factors, 116–17
 - options, 107, 116–17
 - short-term, 116
 - treatment-resistant, pharmacotherapy, 115, 116
 - versus anxiety disorders, 106
- PANSS (Positive and Negative Symptom Scale), 58, 209
- parkinsonism, 63, 69, 72
- Parkinson's disease, 291, 309
- paroxetine, 1
 - in acute bipolar depression treatment, 29, 31, 32
 - in binge-eating disorder treatment, 237
 - dose–response relationships, 179
 - drug-switching studies, 13
 - effectiveness, 4
 - efficacy, 92, 96, 99
 - in generalized anxiety disorder treatment, 91–2
 - treatment duration, 97
 - in obsessive-compulsive disorder treatment, 171, 175–6
- P450 enzyme inhibition, 337
- in panic disorder treatment, 109, 111–12
- platelet binding, 89

356 Index

- paroxetine (*cont.*)
 in posttraumatic stress disorder treatment, 125, 126
 relapse rates, 184–6
 in social anxiety disorder treatment, 142–3, 156, 158
 versus citalopram, 90
 versus escitalopram, 91, 97–8
 versus placebo, 91–2, 96, 142–3, 171
 versus venlafaxine, 181–2
 withdrawal effects, 183–4
 patient compliance *see* adherence
 Patient Impression of Change–Social Phobia Scale, 141
 Paxil *see* paroxetine
 PD *see* panic disorder (PD)
 PDS (Progressive Deterioration Scale), 301
 pemoline *see* magnesium pemoline
 perhenazine, with amitriptyline, 322
 P-gp *see* P-glycoprotein (P-gp)
 pharmacokinetics
 drug interactions, 321–2
 mechanisms, 327–36
 principles, 324–7
 pharmacotherapy
 acute bipolar depression, 28–35
 acute mania, 23–8
 Alzheimer's disease, 290–314
 duration, 306–7
 treatment-resistant, 313–14
 attention-deficit hyperactivity disorder, 255–79
 drug classes, 259, 260, 261, 262, 263
 duration, 278–9
 bipolar disorder prophylaxis, 35–44
 eating disorders, 204–45
 effectiveness, 292
 efficacy, 292
 efficiency, 292
 generalized anxiety disorder, 88–99
 duration, 97–8
 treatment-resistant, 98
 major depressive disorder, 3–10
 duration, 10–12
 treatment-resistant, 12–15
 obsessive-compulsive disorder, 165–93
 duration, 182–7
 treatment-resistant, 187–92
 panic disorder, 105–17
 duration, 114–15
 treatment-resistant, 115
 posttraumatic stress disorder, 121–30
 duration, 127–8
 treatment-resistant, 128–9
 with psychotherapy, 98, 107, 115, 230–1
 schizophrenia, 56–78
 treatment-resistant, 72–8
 social anxiety disorder, 137–60
 duration, 155–7
 treatment-resistant, 157–8
 phenelzine, 8–9, 125, 273
 in bulimia nervosa treatment, 222
 in panic disorder treatment, 109, 115
 in posttraumatic stress disorder treatment, 125, 127
 in social anxiety disorder treatment, 139–41, 152, 153, 154–6
 versus fluoxetine, 168, 171
 versus moclobemide, 141
 DL-phenylalanine, 278
 phenylisopropylamines, 272
 phenytoin, in bulimia nervosa treatment, 228
 pheochromocytoma, 106
 pimozone, 78
 in anorexia nervosa treatment, 207
 drug augmentation, 190
 pindolol
 in attention-deficit hyperactivity disorder treatment, 277
 drug augmentation, 190
 in social anxiety disorder treatment, 158
 piracetam
 activity, 311
 in Alzheimer's disease treatment, 311
 cognitive impairment studies, 311
 indications, 311
 structure, 311
 plasma drug concentration, steady-state, 326
 platelets
 benzodiazepine binding sites, 89
 binding, 89
 polypharmacy
 in acute mania treatment, 28
 in bipolar disorder prophylaxis, 28, 43–4
 evidence-based, 22
 population change, effects on
 obsessive-compulsive disorder studies, 172
 Positive and Negative Symptom Scale (PANSS), 58, 209

357 **Index**

- positron emission tomography (PET),
 - attention-deficit hyperactivity disorder studies, 255–6
- postmenopausal women, hormone replacement therapy, 312
- posttraumatic stress disorder (PTSD)
 - comorbidity, 121
 - costs, 121
 - definition, 121
 - diagnosis, 121–2
 - maintenance treatment, 127–8
 - neurotransmitter dysregulation, 122
 - pharmacotherapy
 - dosage issues, 127
 - duration, 127–8
 - effectiveness, 125
 - evidence-based, 121–30
 - first-line, 125–7
 - study resources, 122
 - trials, 122–5
 - prevalence, 121
 - recognition, 121
 - study resources, 122
 - subtypes, 121
 - treatment-resistant
 - drug augmentation, 128
 - pharmacotherapy, 128–9
- pregabalin, 89
 - efficacy, 99
 - in generalized anxiety disorder treatment, 94–5
 - versus placebo, 94
- PREMEDLINE, searches, 139
- presenile dementia
 - age of onset, 290
 - etiology, 290
- progesterone, trials, 312
- Progressive Deterioration Scale (PDS), 301
- prokinetic agents, in anorexia nervosa treatment, 211–14, 215
- prolactin
 - antipsychotic effects, 77
 - elevated levels, 77
- propranolol
 - in attention-deficit hyperactivity disorder treatment, 277
 - in generalized anxiety disorder treatment, 96
 - in non-generalized social anxiety disorder treatment, 159
 - in panic disorder treatment, 107
 - in posttraumatic stress disorder treatment, 129
- protein binding
 - altered, 329–31
 - displacement interactions, 330
 - in drug interactions, 327
 - reversibility, 330
- protriptyline, in attention-deficit hyperactivity disorder treatment, 270
- Prozac *see* fluoxetine
- pseudoresistance, 12
- psychiatry, drug interactions, 321–3
- PsychInfo, 90, 139
 - searches, 166
- PsychLit, 2
 - searches, 122
- psychoactive drugs
 - drug interactions, 320–1, 332
 - metabolism, 331
 - and panic disorder, 106
 - protein binding, 327
- psychodynamic psychotherapy, in panic disorder treatment, 107
- psychosis, stimulant-induced, 264
- psychotherapy
 - in anorexia nervosa treatment, 211
 - interpersonal, 231
 - in obsessive-compulsive disorder treatment, 174–5
 - with pharmacotherapy, 98, 107, 115, 230–1
 - psychodynamic, 107
 - supportive, 230–1
 - in treatment-resistant social anxiety disorder, 158
 - see also* behavior therapy; cognitive-behavioral therapy (CBT); exposure therapy
- psychotropics, in generalized anxiety disorder treatment, 94–7
- PTSD *see* posttraumatic stress disorder (PTSD)
- Q statistic, 152
- QT interval prolongation, antipsychotic-induced, 78
- Quality of Life, 301
- quetiapine
 - in acute mania treatment, 27
 - drug augmentation, 191
 - maintenance studies, 65
 - meta-analyses, 65
 - in posttraumatic stress disorder treatment, 129
 - in resistant schizophrenia treatment, 73–4
 - in schizophrenia treatment, 63–5

358 Index

- quetiapine (*cont.*)
 versus atypical antipsychotics, 65
 versus conventional antipsychotics, 64–5
 versus placebo, 63–4
- random effects model, 152
 versus fixed-effects model, 150
- randomized controlled trials (RCTs), bias issues, 27
- reboxetine, in panic disorder treatment, 109
- recombinant human growth hormone, 218, 219
- relapse, concept of, 183
- Remeron *see* mirtazapine
- Reminyl *see* galantamine
- Research Unit on Pediatric Psychopharmacology
 Anxiety Study Group, 159
- reserpine, depression induction, 1
- reversible inhibitors of monoamine oxidase
 (RIMAs), 273
 development, 2
 effectiveness, 5–6
 in major depressive disorder treatment, 5–6
 in posttraumatic stress disorder, 125
 in social anxiety disorder treatment, 141–2, 155
- RIMAs *see* reversible inhibitors of monoamine
 oxidase (RIMAs)
- risperidone, 23
 in acute bipolar depression treatment, 31
 in acute mania treatment, 26
 in anorexia nervosa treatment, 207–9
 in bipolar disorder prophylaxis, 40
 drug augmentation, 190–1
 injection, long-acting, 58–9
 maintenance treatment, 60
 meta-analyses, 60–1
 in posttraumatic stress disorder treatment, 129
 in resistant schizophrenia treatment, 72–3
 in schizophrenia treatment, 57, 72
 relapse rates, 60
 side-effects, 59–60
 versus atypical antipsychotics, 59–60
 versus cognitive-behavioral therapy, 71
 versus conventional antipsychotics, 58
 versus olanzapine, 59, 63
 versus placebo, 57–8
- Ritalin *see* methylphenidate
- Ritalin LA
 in attention-deficit hyperactivity disorder
 treatment, 266–7
 dosage issues, 266
 versus placebo, 266–7
- rivastigmine
 in Alzheimer's disease treatment, 294, 297
 benefits, 298
 risk factors, 299
 cost-effectiveness, 304–5
 in dementia with Lewy bodies treatment, 295
 dosage issues, 295, 303
 drug interactions, 304
 side-effects, 302
 titration schemes, 302
 trials, 301
 versus donepezil, 302, 303
 versus placebo, 301
- Rökan *see* EGB 761
- saccadic eye movement velocity, 89
- St. John's wort, 329
- SARIs (serotonin-2 antagonist/reuptake
 inhibitors), 228–30
- schizophrenia, 27, 40
 first-episode, 72
 pharmacotherapy
 evidence-based, 56–78
 first-line, 57–72
 prepsychotic period, 71–2
 relapse rates, 60
 special populations, 71–2
 treatment-resistant, pharmacotherapy, 72–8
- SCID-IV (Structured Clinical Interview for
 DSM-IV Axis IV), 121–2
- SDS (social disability scale), 140
- selective serotonin reuptake inhibitors (SSRIs), 1,
 89
 advantages, 4–5
 in anorexia nervosa treatment, 211, 212
 and attention-deficit hyperactivity disorder,
 273–4
 with benzodiazepines, 110, 114, 115
 in binge-eating disorder treatment, 234–7
 in bulimia nervosa treatment, 222–7, 233, 236
 dose-response relationship, 3–4
 drug interactions, 322–3
 drug switching, 187–8
 studies, 13
 effectiveness, 4, 7
 efficacy, 4, 99
 in generalized anxiety disorder treatment, 90–3,
 96–7
 in major depressive disorder treatment, 3–5,
 15

359 **Index**

- in obsessive-compulsive disorder treatment, 166, 169, 172, 176–8
 - response rates, 173
 - in panic disorder treatment, 108, 109, 110, 111–12, 114
 - platelet binding, 89
 - in posttraumatic stress disorder treatment, 122, 125–7, 130
 - response, sex differences, 9
 - side-effects, 127, 176–8
 - in social anxiety disorder treatment, 142–5, 148, 149, 151, 152, 153–4
 - trials, 8–9
 - with tricyclic antidepressants, 274
 - versus clomipramine, 173–4, 176, 177, 181
 - versus placebo, 172, 179
 - versus tricyclic antidepressants, 110, 111–12, 113–14
- selegiline
- in Alzheimer's disease treatment, 308–9
 - mechanisms, 308
- senile dementia
- and Alzheimer's disease compared, 290
 - use of term, 290
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D), 6
- study goals, 16–17
- serotonergic system, 109, 206
- serotonin, 1, 271
- and eating disorders, 206
 - and generalized anxiety disorder, 89
 - in obsessive-compulsive disorder, 166, 181
 - and posttraumatic stress disorder, 122
- serotonin-norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)
- efficacy, 99
 - in social anxiety disorder treatment, 154
- serotonin receptor antagonists, 1
- serotonin reuptake inhibitors (SRIs)
- in acute bipolar depression treatment, 32, 33
 - drug augmentation, 188, 190–1
 - drug switching, 187–8
 - in obsessive-compulsive disorder treatment, 168–9
 - with depression, 181
 - direct comparisons, 175–6
 - long-term, 182
 - meta-analyses, 173
 - versus psychotherapy, 174–5
 - versus nonserotonergic antidepressants, 168–9
 - see also* selective serotonin reuptake inhibitors (SSRIs)
- serotonin-2 antagonist/reuptake inhibitors (SARIs), in bulimia nervosa treatment, 228–30
- sertindole
- maintenance studies, 67–8
 - meta-analyses, 68
 - in schizophrenia treatment, 67–8
 - suspended in UK, 78
 - versus conventional antipsychotics, 67
 - versus placebo, 67
- sertraline, 1
- in acute bipolar depression treatment, 33
 - axis II personality disorder studies, 8
 - in binge-eating disorder treatment, 237
 - dose–response relationships, 179–80
 - drug augmentation, 14
 - drug-switching studies, 13
 - effectiveness, 4
 - efficacy, 96, 99
 - in generalized anxiety disorder treatment, 92–3
 - in obsessive-compulsive disorder treatment, 170, 175–6, 182
 - long-term, 183
 - in panic disorder treatment, 109
 - in posttraumatic stress disorder treatment, 125, 126, 128
 - response, sex differences, 9
 - in social anxiety disorder treatment, 144, 148, 156
 - versus citalopram, 90
 - versus clomipramine, 174–5
 - versus desipramine, 181
 - versus exposure therapy, 144
 - versus placebo, 92–3, 144, 170
- Serzone *see* nefazodone
- sexual dysfunction, risperidone-induced, 59, 77
- Sheehan Disability Scale, 143, 145, 172
- sick sinus syndrome, 304
- sleep disturbances, stimulant-induced, 258–63
- smoking, and Alzheimer's disease, 293–4
- smoking risk, and attention-deficit hyperactivity disorder, 277
- SNAP rating scale, 268–9
- SNRIs *see* serotonin-norepinephrine (noradrenaline) reuptake inhibitors (SNRIs)

360 Index

- social anxiety disorder
 - age of onset, 137
 - characteristics, 137
 - comorbidity, 154, 157
 - diagnostic criteria, 137
 - effects, 137
 - meta-analyses, 146–52
 - Blanco *et al.*, 151–2, 153
 - Fedoroff and Taylor, 149–51
 - Gould *et al.*, 147–9
 - Van der Linden *et al.*, 149
 - pharmacotherapy
 - drug selection criteria, 152–5
 - effect size, 148
 - evidence-based, 137–60
 - first-line, 139–55
 - future research, 159–60
 - non-adherence, 157
 - relapse, 156–7
 - sex differences, 148, 150
 - treatment duration, 155–7
 - trials, 139–46
 - placebo-controlled studies, 138
 - prevalence, 137
 - study resources, 137–9
 - subtypes, 137
 - treatment, 137
 - treatment outcomes
 - long-term, 148–9
 - measures, 147–8
 - treatment-resistant
 - causes, 157–8
 - drug augmentation, 158
 - management, 158
 - pharmacotherapy, 157–8
 - psychotherapy, 158
 - see also* generalized anxiety disorder (GAD); non-generalized anxiety disorder
- social disability scale (SDS), 140
- social phobia *see* social anxiety disorder
- Social Phobia Inventory (SPIN), 146
- SPT (supportive psychotherapy), 230–1
- SRI *see* serotonin reuptake inhibitors (SRIs)
- SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
- STAI (State and Trait Anxiety Inventory), 140
- STAR*D *see* Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
- State and Trait Anxiety Inventory (STAI), 140
- statins, in Alzheimer's disease treatment, 313
- stimulants
 - analog classroom paradigms, 265
 - in attention-deficit hyperactivity disorder
 - treatment, 257–68
 - delivery systems, 265
 - disadvantages, 268–9
 - drug holidays, 265
 - long-term effects, 264–5
 - new generation, 265–8
 - side-effects, 258–65
 - structure, 257
 - and substance abuse, 264, 268–9
 - versus tricyclic antidepressants, 270–1
- streptococcal infection, 191
- stress, and bipolar disorder, 22
- Structured Clinical Interview for DSM-IV Axis IV (SCID-IV), 121–2
- subdural hematoma, 310
- substance abuse
 - and attention-deficit hyperactivity disorder, 264
 - and bipolar disorder, 22
 - and social anxiety disorder, 154
 - and stimulants, 268–9
- sudden death, children, 276–7
- suicidality, 171
- suicide
 - and bipolar disorder, 22
 - lithium prophylaxis, 37–8
- sulpiride
 - in anorexia nervosa treatment, 207
 - drug augmentation, 190
- sumatriptan, and treatment-resistant obsessive-compulsive disorder, 191
- supportive psychotherapy (SPT), in bulimia nervosa treatment, 230–1
- tachyphylaxis, 265
- tacrine
 - in Alzheimer's disease treatment, 294
 - side-effects, 294
- Tanakan *see* EGb 761
- tardive dyskinesia (TD), 40
- TCAs *see* tricyclic antidepressants (TCAs)
- TD (tardive dyskinesia), 40
- Tebonin *see* EGb, 761
- terpene lactones, 310
- terpenoids, 310
- tetrahydrocannabinol (THC)
 - in anorexia nervosa treatment, 214–16
 - side-effects, 216

361 Index

- Texas Medication Algorithm Project (TMAP), 6, 17
- thalamus, 89
- THC *see* tetrahydrocannabinol (THC)
- thioridazine, 78
- d*-threo-methylphenidate *see* dexmethylphenidate
- thrombocytes *see* platelets
- thyroid, hyperfunction, 106
- thyroid hormone, drug augmentation, 14, 16
- tic disorders, 190, 271
- stimulant-induced, 264
- TMAP (Texas Medication Algorithm Project), 6, 17
- topiramate, 25
- in acute bipolar depression treatment, 30
 - in binge-eating disorder treatment, 238, 239
 - in bipolar disorder prophylaxis, 38
 - in posttraumatic stress disorder treatment, 128–9
- Tourette's syndrome, 190, 275, 276
- transcranial magnetic stimulation, 191
- tranylcypromine, 273
- in acute bipolar depression treatment, 32
- trazodone, 1
- in bulimia nervosa treatment, 228–30
 - effectiveness, 5
 - in posttraumatic stress disorder treatment, 126
 - versus imipramine, 95
- tricyclic antidepressants (TCAs), 1
- in acute bipolar depression treatment, 32
 - in anorexia nervosa treatment, 209–11
 - in attention-deficit hyperactivity disorder treatment, 269–72
 - with benzodiazepines, 115
 - in binge-eating disorder treatment, 234, 235
 - and bipolar disorder, 41
 - in bulimia nervosa treatment, 219–22
 - drug augmentation, 16
 - effectiveness, 7
 - effects on cardiovascular system, 271–2
 - efficacy, 4
 - and elderly, 10
 - in generalized anxiety disorder treatment, 95
 - limitations, 15, 99
 - in panic disorder treatment, 108, 109, 110, 111–12
 - in posttraumatic stress disorder treatment, 125, 127
 - response, sex differences, 9
 - with selective serotonin reuptake inhibitors, 274
 - side-effects, 127, 211, 271–2
 - tolerance, 7
 - trials, 8–9
 - versus selective serotonin reuptake inhibitors, 110, 111–12, 113–14
 - versus stimulants, 270–1
- trifluoperazine
- efficacy, 96
 - in generalized anxiety disorder treatment, 96
- triiodothyronine, 14
- L-tryptophan, in obsessive-compulsive disorder treatment, 181
- L-tyrosine, 278
- UGTs *see* uridine glucuronyltransferases (UGTs)
- unipolar disorder
- diagnosis, 12
 - prevalence, 22
 - recurrence, 11
- uridine glucuronyltransferases (UGTs), 331, 336
- in drug metabolism, 328
- valproate, 23
- in acute bipolar depression treatment, 29–30
 - in acute mania treatment, 23–5
 - antidepressant activity, 30
 - in bipolar disorder prophylaxis, 38, 39–40, 43
 - drug clearance, 326–7
 - in posttraumatic stress disorder treatment, 128–9
- vascular dementia, 291, 294
- pharmacotherapy, 295–8
- venlafaxine, 2, 89, 274
- in acute bipolar depression treatment, 32, 33
 - dose–response relationship, 94
 - drug switching, 187–8
 - drug-switching studies, 13
 - effectiveness, 5, 15
 - efficacy, 96, 99
 - in generalized anxiety disorder treatment, 93–4
 - treatment duration, 97
 - in obsessive-compulsive disorder treatment, 181–2
 - in posttraumatic stress disorder treatment, 126
 - in social anxiety disorder treatment, 145, 154
 - versus placebo, 93, 96, 145
 - versus pregabalin, 94–5
- verapamil, 27
- vigabatrin, in posttraumatic stress disorder treatment, 128–9

362 Index

- vitamin E
 - in Alzheimer's disease treatment, 309–10
 - definition, 309
 - occurrence, 309
 - supplements, 309
 - versus placebo, 309–10
- vitamin supplements, in bipolar disorder
 - prophylaxis, 42
- war veterans, posttraumatic stress disorder, 125
- weight gain
 - and anorexia nervosa, 207
 - antipsychotic-induced, 76–7
 - and binge-eating disorder, 204–5
 - and bulimia nervosa, 204
 - olanzapine-induced, 72
 - risperidone-induced, 59
 - sertindole-induced, 68
 - see also* eating disorders (EDs)
- Wellbutrin *see* bupropion
- WHO (World Health Organization), 1
- World Council on Anxiety, 178
- World Health Organization (WHO), 1
- Writing Group for the Women's Health Initiative
 - Investigators, 312
- Yale–Brown Obsessive Compulsive Scale (Y-BOCS), 165, 167, 183, 188
 - citalopram studies, 172
 - clomipramine studies, 174
 - fluoxetine studies, 170
 - fluvoxamine studies, 169, 190
 - paroxetine studies, 171, 176, 182
 - quetiapine studies, 191
 - risperidone studies, 190
 - sertraline studies, 170
 - treatment–response studies, 187
 - venlafaxine studies, 182
- Y-BOCS *see* Yale–Brown Obsessive Compulsive Scale (Y-BOCS)
- yohimbine, effects on noradrenergic system, 89
- zimelidine, 169
 - in panic disorder treatment, 111–12
- zinc deficiency, and anorexia nervosa, 216
- zinc sulfate, 216
- zinc supplementation, in anorexia nervosa
 - treatment, 216
- ziprasidone, 27
 - in acute bipolar depression treatment, 31
 - intramuscular, 66
 - maintenance studies, 66
 - meta-analyses, 66–7
 - QT interval prolongation, 78
 - in schizophrenia treatment, 65–7
 - side-effects, 65
 - versus conventional antipsychotics, 66
 - versus placebo, 65–6
- Zoloft *see* sertraline
- zonisamide, 31